28 results
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
12 Mar 24
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
8:30am
to join the Atossa Therapeutics board and look forward to furthering the Company’s mission to prevent breast cancer, as well as to improve treatment
8-K
EX-1.1
ATOS
Atossa Therapeutics Inc
23 Mar 21
Entry into a Material Definitive Agreement
6:01am
, with offices located at 555 Mission Street, Suite 3000, San Francisco, California 94105.
“Disclosure Schedules” means the Disclosure Schedules of the Company
S-3MEF
ATOS
Atossa Therapeutics Inc
22 Mar 21
Registration of additional securities for an S-3
7:30am
to:
Ryan A. Murr
Gibson, Dunn & Crutcher LLP
555 Mission Street
San Francisco, California 94105
Telephone: (415) 393-8373
Kyle Guse
Chief Financial
8-K
EX-1.1
50p5x1 p4ak4
8 Jan 21
Entry into a Material Definitive Agreement
9:00am
8-K
EX-1.1
e1vuj9
21 Dec 20
Entry into a Material Definitive Agreement
9:10am
8-K
EX-1.1
rs4gnyqdm9ct7plj3g6
14 Dec 20
Entry into a Material Definitive Agreement
4:16pm
8-K
EX-1.1
p3vl beyb61a1
25 Sep 20
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-1.1
ut8qucnoj v8wz
10 Feb 20
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
xhe xq2bz2hsnerb3xs
13 Sep 18
Atossa Genetics Announces Preliminary Results from
12:00am
8-K
EX-4.1
6ox0ky4t4w
31 May 18
Material Modifications to Rights of Security Holders
6:33am
FWP
3gm4f6 ev9
16 May 18
Free writing prospectus
2:39pm